Xceleron www.xceleron.com
是一家從大學(xué)衍生出來的公司，這家公司在約克的中心科學(xué)實(shí)驗(yàn)室有一個重型的回旋加速器質(zhì)譜儀，在藥物開發(fā)的納米技術(shù)應(yīng)用方面處于領(lǐng)先地位。Xceleron公司將利用超靈敏加速質(zhì)譜技術(shù)（AMS）開展研究工作。這個最靈敏的測試裝置可以在臨床研究的早期階段得到藥物代謝表達(dá)譜。這個分析工具可以使藥物研發(fā)人員檢測和測量出超低水平的已知和未知代謝產(chǎn)物的數(shù)據(jù)，這是用其他分析技術(shù)所不能得到的。

Xceleron Inc
20340 Seneca Meadows Parkway
Germantown, MD, 20876
USA
Email: info@xceleron.com
Phone: +1 240 361 1900
Fax: +1 240 361 1901

A journey toward Pharmaceutical Innovation 
Founded in 1997 in York, UK, Xceleron provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials.
Xceleron pioneered human microtracer techniques as a way to accelerate drug development and has unmatched robust processes and knowledge of experimental design. There are currently 6 drugs on the market that have used Xceleron AMS data in filing, and another 3 in late stages of development. In 2008, the company opened its US facility in Maryland.
Xceleron's experience is especially valuable today because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.
Our services can be tailored specifically for each project. We ensure that all aspects of an early human trial are managed quickly and cost-effectively.
Xceleron has been providing insight into early human drug development for more than 10 years and has conducted more GLP and GCP studies than any other CRO of its type.